Nicholas Company Inc. increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 342,570 shares of the company’s stock after acquiring an additional 190 shares during the period. Johnson & Johnson comprises 1.1% of Nicholas Company Inc.’s holdings, making the stock its 28th largest position. Nicholas Company Inc.’s holdings in Johnson & Johnson were worth $47,713,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently bought and sold shares of the stock. Crewe Advisors LLC boosted its position in Johnson & Johnson by 725.9% during the second quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after purchasing an additional 196 shares in the last quarter. Evolution Wealth Advisors LLC purchased a new position in Johnson & Johnson during the fourth quarter worth approximately $40,000. Permanens Capital L.P. boosted its position in Johnson & Johnson by 50.0% during the second quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock worth $42,000 after purchasing an additional 100 shares in the last quarter. Thor Advisors LLC purchased a new position in Johnson & Johnson during the first quarter worth approximately $69,000. Finally, Personal Wealth Partners purchased a new position in Johnson & Johnson during the second quarter worth approximately $73,000. 72.12% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages have issued reports on JNJ. Goldman Sachs Group set a $169.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price target on the stock. in a research report on Thursday, July 18th. Raymond James lowered their price target on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 17th. Finally, Barclays began coverage on Johnson & Johnson in a research report on Friday, June 21st. They set a “hold” rating and a $140.00 price target on the stock. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $150.60.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.42 by $0.16. The business had revenue of $20.56 billion for the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The business’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.10 earnings per share. As a group, analysts expect that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were given a $0.95 dividend. The ex-dividend date was Monday, August 26th. This represents a $3.80 annualized dividend and a dividend yield of 2.92%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Why Dividend Stocks May Be Right for You
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.